O	0	10	Predictive
O	11	18	factors
O	19	21	of
O	22	32	pathologic
O	33	41	complete
O	42	50	response
O	51	54	and
O	55	63	clinical
O	64	69	tumor
O	70	81	progression
O	82	87	after
B-intervention	88	100	preoperative
I-intervention	101	113	chemotherapy
O	114	116	in
B-eligibility	117	125	patients
I-eligibility	126	130	with
I-eligibility	131	136	stage
I-eligibility	137	139	II
I-eligibility	140	143	and
I-eligibility	144	147	III
I-eligibility	148	154	breast
I-eligibility	155	161	cancer
O	161	162	.

O	163	167	This
O	168	173	study
O	174	179	aimed
O	180	182	to
O	183	189	define
O	190	200	predictive
O	201	208	factors
O	209	211	of
O	212	222	pathologic
O	223	231	complete
O	232	240	response
O	241	242	(
O	242	245	pCR
O	245	246	)
O	247	250	and
O	251	258	disease
O	259	270	progression
O	271	273	in
B-eligibility	274	279	stage
I-eligibility	280	282	II
I-eligibility	283	286	and
I-eligibility	287	290	III
I-eligibility	291	297	breast
I-eligibility	298	304	cancer
I-eligibility	305	313	patients
O	313	314	.

B-total-participants	315	320	Three
I-total-participants	321	328	hundred
I-total-participants	329	335	thirty
I-total-participants	335	336	-
I-total-participants	336	341	eight
O	342	350	patients
O	351	355	were
O	356	364	included
O	365	367	in
O	368	371	the
O	372	377	study
O	377	378	.

O	379	387	Patients
O	388	391	had
O	392	400	received
O	401	413	preoperative
O	414	426	chemotherapy
O	427	429	as
O	430	437	follows
O	437	438	:
B-intervention-participants	439	442	101
O	443	446	had
O	447	458	doxorubicin
O	459	463	plus
O	464	480	cyclophosphamide
O	481	482	(
O	482	484	AC
O	484	485	)
O	485	486	;
B-intervention-participants	487	489	91
O	490	493	had
O	494	505	doxorubicin
O	506	510	plus
O	511	520	docetaxel
O	520	521	;
B-intervention-participants	522	525	103
O	526	529	had
O	530	539	docetaxel
O	540	544	plus
O	545	557	capecitabine
O	557	558	;
O	559	562	and
B-intervention-participants	563	565	43
O	566	569	had
O	570	580	paclitaxel
O	581	585	plus
O	586	597	gemcitabine
O	597	598	.

O	599	600	A
O	601	604	pCR
O	605	608	was
O	609	616	defined
O	617	619	as
O	620	623	the
O	624	631	absence
O	632	634	of
O	635	643	residual
O	644	652	invasive
O	653	662	carcinoma
O	663	665	in
O	666	669	the
O	670	676	breast
O	676	677	.

O	678	681	The
O	682	690	majority
O	691	693	of
O	694	702	patients
O	703	704	(
O	704	706	73
O	706	707	%
O	707	708	)
O	709	713	were
O	714	727	premenopausal
O	728	732	with
O	733	734	a
O	735	741	median
O	742	745	age
O	746	748	of
B-age	749	751	44
I-age	752	753	(
I-age	753	758	range
I-age	758	759	,
I-age	760	762	21
I-age	762	763	-
I-age	763	765	76
I-age	765	766	)
I-age	767	772	years
O	772	773	.

O	774	779	Fifty
O	779	780	-
O	780	784	four
O	785	793	patients
O	794	795	(
O	795	797	16
O	797	798	%
O	798	799	)
B-outcome	800	808	achieved
I-outcome	809	812	pCR
O	813	816	and
O	817	821	were
O	822	833	distributed
O	834	839	among
O	840	843	the
O	844	845	4
O	846	852	breast
O	853	859	cancer
O	860	868	subtypes
O	869	871	as
O	872	879	follows
O	879	880	:
O	881	883	10
O	883	884	%
O	885	887	of
O	888	896	patients
O	897	901	with
O	902	903	-
O	903	905	ER
O	906	908	or
O	909	911	PR
O	911	912	+
O	912	913	/
O	913	917	HER2
O	917	918	-
O	918	919	,
O	920	922	13
O	922	923	%
O	924	928	with
O	929	931	ER
O	932	934	or
O	935	937	PR
O	937	938	+
O	938	939	/
O	939	943	HER2
O	943	944	+
O	944	945	,
O	946	948	33
O	948	949	%
O	950	954	with
O	955	957	ER
O	957	958	-
O	958	959	/
O	959	961	PR
O	961	962	-
O	962	963	/
O	963	967	HER2
O	967	968	+
O	968	969	,
O	970	973	and
O	974	976	19
O	976	977	%
O	978	982	with
O	983	985	ER
O	985	986	-
O	986	987	/
O	987	989	PR
O	989	990	-
O	990	991	/
O	991	995	HER2
O	995	996	-
O	996	997	(
O	997	998	p
O	999	1000	=
O	1001	1002	0
O	1002	1003	.
O	1003	1006	001
O	1006	1007	)
O	1007	1008	.

O	1009	1015	Taxane
O	1015	1016	-
O	1016	1026	containing
O	1027	1034	regimen
O	1035	1036	(
O	1036	1037	p
O	1038	1039	=
O	1040	1041	0
O	1041	1042	.
O	1042	1045	042
O	1045	1046	)
O	1047	1050	and
O	1051	1057	Breast
O	1058	1064	cancer
O	1065	1072	subtype
O	1073	1074	(
O	1074	1075	p
O	1076	1077	=
O	1078	1079	0
O	1079	1080	.
O	1080	1083	005
O	1083	1084	)
O	1085	1089	were
O	1090	1101	significant
O	1102	1112	predictive
O	1113	1122	variables
O	1123	1126	for
B-outcome	1127	1130	pCR
O	1130	1131	.

O	1132	1134	On
O	1135	1138	the
O	1139	1144	other
O	1145	1149	hand
O	1149	1150	,
O	1151	1164	significantly
O	1165	1169	more
O	1170	1178	patients
O	1179	1182	who
O	1183	1191	received
O	1192	1195	non
O	1195	1196	-
O	1196	1202	taxane
O	1202	1203	-
O	1203	1213	containing
O	1214	1221	regimen
O	1222	1223	(
O	1223	1225	AC
O	1225	1226	)
O	1227	1238	experienced
B-outcome	1239	1241	no
I-outcome	1242	1250	response
O	1251	1252	(
O	1252	1253	p
O	1254	1255	=
O	1256	1257	0
O	1257	1258	.
O	1258	1261	001
O	1261	1262	)
O	1263	1265	or
B-outcome	1266	1277	progression
O	1278	1279	(
O	1279	1280	p
O	1281	1282	=
O	1283	1284	0
O	1284	1285	.
O	1285	1288	006
O	1288	1289	)
O	1289	1290	.

O	1291	1299	Patients
O	1300	1304	with
O	1305	1307	ER
O	1307	1308	-
O	1308	1309	/
O	1309	1311	PR
O	1311	1312	-
O	1312	1313	/
O	1313	1317	HER2
O	1317	1318	+
O	1319	1325	tumors
O	1326	1329	and
O	1330	1335	those
O	1336	1339	who
O	1340	1348	received
O	1349	1355	taxane
O	1355	1356	-
O	1356	1366	containing
O	1367	1374	regimen
O	1375	1383	achieved
O	1384	1385	a
O	1386	1392	higher
O	1393	1396	pCR
O	1397	1401	rate
O	1401	1402	,
O	1403	1408	while
O	1409	1422	significantly
O	1423	1427	more
O	1428	1436	patients
O	1437	1446	developed
O	1447	1452	tumor
O	1453	1464	progression
O	1465	1467	by
O	1468	1480	preoperative
O	1481	1484	non
O	1484	1485	-
O	1485	1491	taxane
O	1491	1492	-
O	1492	1502	containing
O	1503	1510	regimen
O	1511	1512	(
O	1512	1514	AC
O	1514	1515	)
O	1516	1524	compared
O	1525	1527	to
O	1528	1533	those
O	1534	1537	who
O	1538	1546	received
O	1547	1553	taxane
O	1553	1554	-
O	1554	1564	containing
O	1565	1577	chemotherapy
O	1577	1578	.
